礼来公司正在发出警示，根据政府支持的新定价模式，部分使用其GLP-1（胰高血糖素样肽-1）减肥和糖尿病药物的Medicare患者，最终支付的费用可能会高于广受讨论的每月50美元的自付上限。

　　该计划是美国医疗保险和医疗补助服务中心（CMS，Centers for Medicare and Medicaid Services）“BALANCE”计划的一部分，该名称是“实现全面健康的更好生活方式与营养方法”（Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth）的缩写。

　　该模式于去年12月宣布，旨在通过允许CMS直接与礼来公司和诺和诺德公司等制造商进行谈判，使GLP-1药物更加 affordable（价格可负担）。

　　根据该计划，参与项目的Medicare计划中的大多数受益人，预计每月支付约50美元即可获得一剂GLP-1药物。

　　但礼来公司表示，不同计划的具体情况可能不尽相同。该公司在一份声明中指出，虽然大多数Medicare选项将遵守50美元的自付费用上限，但在少数基础Medicare D部分计划中，费用分摊情况仍可能存在差异。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.